7. At the end⌠you will learnAt the end⌠you will learn
⢠Kidney disease can beKidney disease can be aa silent killersilent killer
⢠Childhood Nephrotic Syndrome is mostly curableChildhood Nephrotic Syndrome is mostly curable
⢠APSGN mostly recoversAPSGN mostly recovers;; does nor recurdoes nor recur
⢠HematuriaHematuria in small children is usuallyin small children is usually harmlessharmless
⢠With ageing most of us develop kidney diseaseWith ageing most of us develop kidney disease
⢠ARF in most cases can be preventedARF in most cases can be prevented
APSGN: ac. Post-strep. Glomerulonephritis. ARF: ac. Renal failureAPSGN: ac. Post-strep. Glomerulonephritis. ARF: ac. Renal failure
77
11. Importance of kidneyImportance of kidney
⢠MainMain waste excreterwaste excreter
⢠MaintainsMaintains fluid-, electrolyte- & AB Balancefluid-, electrolyte- & AB Balance
⢠MakesMakes erythropoietinerythropoietin
⢠MakesMakes thrombopoietinthrombopoietin
⢠Excretes someExcretes some drugsdrugs
⢠Biotransforms/activatesBiotransforms/activates VDVD
ABB: acid base balance. VD: vitamin DABB: acid base balance. VD: vitamin D
1111
12. Peculiarities of Kidney DiseasesPeculiarities of Kidney Diseases
⢠May be asymptomaticMay be asymptomatic (silent killer)(silent killer)
⢠Symptoms can beSymptoms can be nonspecificnonspecific
⢠Few physical signsFew physical signs (lab tests are important)(lab tests are important)
⢠May present withMay present with jaundicejaundice in infantsin infants
⢠Important c/ofImportant c/of FTTFTT
⢠Long tract: moreLong tract: more obstruction, complicationsobstruction, complications
1212
17. Micros. H:Micros. H: in a well child: ~in a well child: ~ no testno test
if not x3 times over severalif not x3 times over several
mo.mo.
evaluate if HTN, CKD,evaluate if HTN, CKD,
casturia/proteinuria presentcasturia/proteinuria present
Gross H:Gross H: urine is red/tea/colaurine is red/tea/cola
colored. It is also mostlycolored. It is also mostly
benignbenign
Up to 5 RBC/HPF in urine isUp to 5 RBC/HPF in urine is
normal in childrennormal in children
1717
18. Causes:Causes: The most
frequent: UTIâs, stones
& tumor
GH is more in boys.GH is more in boys.
Assess by CF.Assess by CF.
VCUG is useful inVCUG is useful in
doubtful USG, UTI, ordoubtful USG, UTI, or
voiding problem.voiding problem.
Cystoscopy ifCystoscopy if
persistent or withpersistent or with
ambiguous imagingambiguous imaging
GH: gross hematuria. VCUG : voidingGH: gross hematuria. VCUG : voiding
cystourethrographycystourethrography
"one should
investigate hematuria
rather than treat it"
19. Henoch-Schonlein purpuraHenoch-Schonlein purpura
⢠Classic triad:Classic triad: purpurapurpura (100%),(100%), arthritis/arthralgiaarthritis/arthralgia (80%),(80%), AP (AP (60%)60%)
⢠70% affect kidneys70% affect kidneys
⢠Histologically vasculitis,Histologically vasculitis, IgANIgAN
⢠90% fully recover. May relapseMay relapse
⢠Severe: steroids, azathioprineSevere: steroids, azathioprine
⢠Follow until urine is normalFollow until urine is normal
⢠5-20% of children end in ESRD5-20% of children end in ESRD
IgAN: IgA nephropathy. ESRD: end stage renal diseaseIgAN: IgA nephropathy. ESRD: end stage renal disease
1919
20. 2020
HS Purpuras:HS Purpuras: necrotizingnecrotizing
vasculitis in skinvasculitis in skin smallsmall
BV; usuallyBV; usually extensorextensor
surfaces ofsurfaces of limbs,limbs,
sometimessometimes buttocksbuttocks
A.P., V., gut bleedingA.P., V., gut bleeding::
vasculitis in GITvasculitis in GIT
Renal:Renal: commonest iscommonest is
hematuria. In adults:hematuria. In adults: moremore
severe & maysevere & may dev. to rapidlydev. to rapidly
progressingprogressing
crescentic GNcrescentic GN
21. Wilms T/Nephroblastoma:Wilms T/Nephroblastoma: commonest child kidney Ca.commonest child kidney Ca.
â˘Causes:Causes: unknown, ~genetic. Aniridia sometimes; certainunknown, ~genetic. Aniridia sometimes; certain
UT problems & hemihypertrophy. Most at 3y; rare at 8UT problems & hemihypertrophy. Most at 3y; rare at 8
â˘SS:SS: any of: AP, hematuria, constipation, F, malaise, ANV,any of: AP, hematuria, constipation, F, malaise, ANV,
hernia, FH of Ca., abdo. mass, HTNhernia, FH of Ca., abdo. mass, HTN
â˘Lab.:Lab.: USG, AXR, BUN, Cr. CCr, CXR, CBC, CT abdo, IVU,USG, AXR, BUN, Cr. CCr, CXR, CBC, CT abdo, IVU,
urinalysis, tests to determine spreadurinalysis, tests to determine spread
â˘Rx:Rx: do not press belly.do not press belly. Staging. SurgeryStaging. Surgery asapasap. RadioRx &. RadioRx &
chemo-. often post surgery, depending on stagechemo-. often post surgery, depending on stage
â˘Prognosis:Prognosis: if no spread: 90% cureif no spread: 90% cure
â˘Complications:Complications: Spread to lungs, liver, bone, or brain.Spread to lungs, liver, bone, or brain.
HTN & kidney damage may occur as the result ofHTN & kidney damage may occur as the result of
the tumor or its Rxthe tumor or its Rx.. 2121
24. A Case History of hematuriaA Case History of hematuria
⢠A 12y-boy has hematuria. He has occasional dark urineA 12y-boy has hematuria. He has occasional dark urine
after heavy exerciseafter heavy exercise
⢠No h/o medicine, deafness; no FH of renal d.No h/o medicine, deafness; no FH of renal d.
⢠PE:PE: normal:normal: BP 130/80BP 130/80
⢠Trace proteinuriaTrace proteinuria
⢠10-15 rbc/hpf. No casts10-15 rbc/hpf. No casts
What is the most probable Dx?What is the most probable Dx?
2424
25. Answer: Exercise Induced HematuriaAnswer: Exercise Induced Hematuria
⢠Hematuria: asymptomaticHematuria: asymptomatic
⢠5-10% in the community5-10% in the community
⢠No features of NS/GNNo features of NS/GN
2525
26. Renal Function in NewbornRenal Function in Newborn
GFRGFR
â 5ml/min in first week of life5ml/min in first week of life
â 10ml/min 1-2 mo10ml/min 1-2 mo
â Preterm has lower GFRPreterm has lower GFR
2626
27. TerminologiesTerminologies
Oliguria:Oliguria: hypouresishypouresis, urine output <1mL/kg/h in infants,, urine output <1mL/kg/h in infants,
<0.5 mL/kg/h in children, <400 mL/d in adults.<0.5 mL/kg/h in children, <400 mL/d in adults.
⢠It is a clinical hallmark of renal failure & a criterion forIt is a clinical hallmark of renal failure & a criterion for
Dx & staging AKIDx & staging AKI
⢠It is frequently acute; often the earliest s/of ARF &It is frequently acute; often the earliest s/of ARF &
poses a Dx & Rx challenge to the Dr.poses a Dx & Rx challenge to the Dr.
Anuria:Anuria: oror anuresis anuresis, is passage of <100ml/d., is passage of <100ml/d.
⢠It is often c/by ARF; may also occur due to severe obs.It is often c/by ARF; may also occur due to severe obs.
(kidney stones or T); may occur in ESRD(kidney stones or T); may occur in ESRD
⢠It is a more extreme reduction than oliguriaIt is a more extreme reduction than oliguria
2727
33. ⢠HUS:HUS: destroysdestroys lininglining of BV & RBCof BV & RBC; often c/by; often c/by E. coliE. coli;;
may get ARF or coagulopathymay get ARF or coagulopathy
⢠Alport Syn.:Alport Syn.:  inherited. Hematuria, proteinuria. Moreinherited. Hematuria, proteinuria. More
serious in boys; leads to ESRD, hearing & visual lossserious in boys; leads to ESRD, hearing & visual loss
⢠PKD:PKD: inherited, AD: grape-like cysts in kidneys; destroyinherited, AD: grape-like cysts in kidneys; destroy
kidneys: CKD & ESRDkidneys: CKD & ESRD
HUS: hemolytic uremic syn. PKD: polycystic kidney DHUS: hemolytic uremic syn. PKD: polycystic kidney D
3333
34. ⢠Interstitial Nephritis:Interstitial Nephritis: Inflam. of supporting tissue ofInflam. of supporting tissue of
kidney; can lead to ARF/ESRDkidney; can lead to ARF/ESRD
⢠Renal osteodystrophy:Renal osteodystrophy: RF causing weak bones;RF causing weak bones;
more in dialysis pts.: high PO4/low VDmore in dialysis pts.: high PO4/low VD
⢠RTA:RTA: kidneys fail to remove acids normally: weak bones,kidneys fail to remove acids normally: weak bones,
kidney stones & FTTkidney stones & FTT
RTA: renal tubular acidosisRTA: renal tubular acidosis
3434
35. Acute Kidney InjuryAcute Kidney Injury ((AKIAKI) () (ARFARF))
abrupt loss of RFabrupt loss of RF within 7d.within 7d. c/byc/by low RBFlow RBF (low BP),(low BP),
renotoxins, inflam., or obs. of UTrenotoxins, inflam., or obs. of UT
⢠Dx.:Dx.: typically raised BUN & creatinine, or low UOPtypically raised BUN & creatinine, or low UOP
⢠Complications:Complications: m. acidosis, hyperkalemia, uremia, FEm. acidosis, hyperkalemia, uremia, FE
imbalance, & effects on other systems, death. Moreimbalance, & effects on other systems, death. More
risk of CKDrisk of CKD
⢠CausesCauses areare numerousnumerous. Common:. Common:
â SevereSevere dehydration, sdehydration, shock, ac.hock, ac. hgehge
â BlockageBlockage of renal BV,of renal BV, obstructionobstruction in UTin UT
â Renal trauma, Ac.Renal trauma, Ac. GN, aGN, acc. PN. PN
⢠Rx.:Rx.: underlying cause & supportive like RRTunderlying cause & supportive like RRT
RF: renal function. RBF: renal blood flow. RRT: renal replacement therapy. BV: blood vesselRF: renal function. RBF: renal blood flow. RRT: renal replacement therapy. BV: blood vessel3535
36. CKD (CRF):CKD (CRF): GFR <90ml/min/1.73mGFR <90ml/min/1.73m22
>3 mo>3 mo
5 stages5 stages
⢠GFR 90ml/min/1.73m2GFR 90ml/min/1.73m2 NormalNormal
⢠60-89 âŚ.60-89 âŚ. MildMild
⢠30-59 âŚ.30-59 âŚ. ModerateModerate
⢠15-29 âŚ.15-29 âŚ. SevereSevere
⢠<15/dialysis<15/dialysis E S R DE S R D
3636
37. Causes of CKDCauses of CKD
⢠Systemic:Systemic: DM, HTN,DM, HTN, SLE, HSP, IgAN, APSGN, HIV, HBV, HCVSLE, HSP, IgAN, APSGN, HIV, HBV, HCV
⢠Primary:Primary: FSGS, MGN, MPGNFSGS, MGN, MPGN, crescentic GN,, crescentic GN,
Goodpasture syn.Goodpasture syn.
⢠Vascular:Vascular: Nephrosclerosis, ANCA, HUSNephrosclerosis, ANCA, HUS
⢠Hereditary:Hereditary: Amyloidosis, PKD, Alport syn.Amyloidosis, PKD, Alport syn.
⢠Tubulointerstitial:Tubulointerstitial: drugs/toxins, VUR, obs. uropathydrugs/toxins, VUR, obs. uropathy
ANCAs: Anti-neutrophil cytoplasmic AbANCAs: Anti-neutrophil cytoplasmic Ab:: mainly IgG, against neutrophil & monocytemainly IgG, against neutrophil & monocyte
cytoplasm. Seen in some AID. Particularly associated with systemic vasculitis (ANCAcytoplasm. Seen in some AID. Particularly associated with systemic vasculitis (ANCA
vasculitides)vasculitides)
3737
39. Goodpasture Syn.Goodpasture Syn. ((anti-GBM d.)anti-GBM d.)
⢠Aka Aka pulmo-renal syn. Anti-collagen Ab in lungs:pulmo-renal syn. Anti-collagen Ab in lungs: vasculitis: vasculitis:Â
hemorrhage. Kidneys:hemorrhage. Kidneys: GN (anti-GBM Abs)GN (anti-GBM Abs)
⢠Autoimmune d.;Autoimmune d.; fatalfatal  unless quickly Rxunless quickly Rx..
IgA NephropathyIgA Nephropathy ((Berger DBerger D):): RF is rareRF is rare
Commonest GN in WestCommonest GN in West.. IgA deposits following URTI:IgA deposits following URTI:
silentsilent hematuria; may go for yrshematuria; may go for yrs
⢠Men more. All agesMen more. All ages
⢠No Rx if early/mild with normal BP & <1g 24TUP: if more,No Rx if early/mild with normal BP & <1g 24TUP: if more,
Rx. with ACEI or ARBsRx. with ACEI or ARBs
AID: autoimmune d. GBM: glomerular basement membrane. RF: renal failure. TUP: total urinary AID: autoimmune d. GBM: glomerular basement membrane. RF: renal failure. TUP: total urinaryÂ
proteinprotein
40. Paroxysmal Noc. Hb.uria (PNH)Paroxysmal Noc. Hb.uria (PNH)
Rare.Rare. AcquiredAcquired. Life-threatening d.. Life-threatening d. characterizedcharacterized
byby complement-induced IV hemolysiscomplement-induced IV hemolysis
⢠Some proteins cannot fix to RBCs to protect fromSome proteins cannot fix to RBCs to protect from
complements: hemolysis: Hemoglobinemia & Hb.uria;complements: hemolysis: Hemoglobinemia & Hb.uria;
at night/early morningat night/early morning
⢠Any age. May be f/byAny age. May be f/by aplastic a., AML, MDSaplastic a., AML, MDS
⢠SS:SS: RAP, backache, headache, SoB, clotting; dark urine; easyRAP, backache, headache, SoB, clotting; dark urine; easy
bruisingbruising
4040
MDS:MDS: myelodysplastic syn. SoB: short of breathingmyelodysplastic syn. SoB: short of breathing
41. Investigations for PNHInvestigations for PNH
⢠Pancytopenia, Pancytopenia, Hb.emia & Hb.uriaHb.emia & Hb.uria
⢠Coombs' testCoombs' test
⢠Haptoglobin levelHaptoglobin level
⢠Flow cytometry to measure certain proteinsFlow cytometry to measure certain proteins
⢠Ham (acid hemolysin) testHam (acid hemolysin) test
⢠Sucrose hemolysis testSucrose hemolysis test
⢠Urine hemosiderinUrine hemosiderin
4141
42. Rx for PNHRx for PNH
⢠Steroids/immunosuppressantsSteroids/immunosuppressants
⢠BT. Iron & B9. Blood thinnersBT. Iron & B9. Blood thinners
⢠EculizumabEculizumab  can block hemolysiscan block hemolysis
⢠BMT can cureBMT can cure
⢠Vaccinations against certain types of bacteriaVaccinations against certain types of bacteria
Outlook:Outlook: most people survive >10 y after Dx. Death occurmost people survive >10 y after Dx. Death occur
from thrombosis or bleedingfrom thrombosis or bleeding
BMT: bone marrow transplantBMT: bone marrow transplant
4242
43. Ac NephriticAc Nephritic
(Glomerulonephritic)(Glomerulonephritic) Syn.Syn.
⢠Ac. inflam. of the glomeruli & nephronsAc. inflam. of the glomeruli & nephrons
Nephrotic SyndromeNephrotic Syndrome
⢠Affection of nephrons with leakage ofAffection of nephrons with leakage of
protein (usually noprotein (usually no inflam.) inflam.)
4343
44. GlomerulonephritisGlomerulonephritis
⢠Inflam. & proliferation of glomerular tissue with damage toInflam. & proliferation of glomerular tissue with damage to
basement membrane, mesangium/capillary endoth.basement membrane, mesangium/capillary endoth.
⢠Acute:Acute: hematuria, proteinuria & RBC casts. Often withhematuria, proteinuria & RBC casts. Often with
HTN, edema & impaired RFHTN, edema & impaired RF
⢠Chr.Chr.:: above with scarring of nephrons & progressive RFabove with scarring of nephrons & progressive RF
4444
45. Ac Nephritis: causesAc Nephritis: causes
â Group A StreptococcusGroup A Streptococcus 80%80%
â OthersOthers 20%20%
⢠Systemic:Systemic: HSP,HSP, SLE, IgAN,SLE, IgAN, Goodpasture, gold,Goodpasture, gold,
penicillaminepenicillamine
⢠Infx.:Infx.: staph, pneumococci, Gram-ve, malaria, HBV,staph, pneumococci, Gram-ve, malaria, HBV,
HCV, MMR, HIVHCV, MMR, HIV
⢠Infective endocarditisInfective endocarditis
⢠Renal d:Renal d: MGN, MPGN, FSGS, etc.MGN, MPGN, FSGS, etc.
4545
46. Ac. Post-Strep. Glom. N.Ac. Post-Strep. Glom. N.
⢠15% of all GAS infx.;15% of all GAS infx.; mostly RTI (skin 10%)mostly RTI (skin 10%)
⢠Lag period:Lag period: 2-3w2-3w
⢠2% clinically overt2% clinically overt
⢠No recurrenceNo recurrence
⢠Any Age Any Age (2-15y; 2% <2y; 10% >40y)(2-15y; 2% <2y; 10% >40y)
⢠Boys moreBoys more
⢠Excellent prognosisExcellent prognosis:: <2% MR. 2% Chr. GN<2% MR. 2% Chr. GN
⢠Cerebral vasculitis may occurCerebral vasculitis may occur
GAS: group A streptococciGAS: group A streptococci
4646
47. PathophysiologyPathophysiology
ďś Exact mechanism is unclearExact mechanism is unclear
ďś Strep. itselfStrep. itself does not attack the kidneydoes not attack the kidney
ďś Autoim. d:Autoim. d: both CMI & humoral.both CMI & humoral. Immune complex Immune complexÂ
deposits in glomeruli, activates complement: inflam.deposits in glomeruli, activates complement: inflam.
Kidneys enlarge in ~50%Kidneys enlarge in ~50%
ďś Histology:Histology: swelling of glomeruli, polymorphs infiltrateswelling of glomeruli, polymorphs infiltrate
IF:IF: deposition of Ig & complementdeposition of Ig & complement
4747
49. CFCF of A.P.S.G.N.of A.P.S.G.N.
ď§ Preceding URTI, skin infx. by a few weeksPreceding URTI, skin infx. by a few weeks
ď§ Most common:Most common: edema (puffy face), hematuria (100%,edema (puffy face), hematuria (100%,
gross 30%), & HTN, with/-out oliguriagross 30%), & HTN, with/-out oliguria
95% have at least 2 features, & 40% have all95% have at least 2 features, & 40% have all
ď§ Flank pain (stretching of renal capsule)Flank pain (stretching of renal capsule)
ď§ Weakness, -/+ AP, anorexia, feverWeakness, -/+ AP, anorexia, fever
ď§ Anasarca, SoBAnasarca, SoB,, coughcough
ď§ HTN, HA, LVF, convulsionHTN, HA, LVF, convulsion
HTN: hypertension. HA: headache. HC: highHTN: hypertension. HA: headache. HC: high
Colored.Colored.
4949
50. Edema:Edema: 80-90%.80-90%. Presentation in 60%.Presentation in 60%.
⢠Low RBF due to glomerular hypercellularity: low excretionLow RBF due to glomerular hypercellularity: low excretion
of Na & urine: salt & water retentionof Na & urine: salt & water retention
Hypertension:Hypertension: 60-80%.60-80%. Severe in 50%.Severe in 50%. More in elderly.More in elderly.
Often transient. If persists: indicative of CKD or not APSGNOften transient. If persists: indicative of CKD or not APSGN
⢠Despite Na retention, atrial natriuretic peptide is raised.Despite Na retention, atrial natriuretic peptide is raised.
Kidneys become unresponsive to itKidneys become unresponsive to it
⢠Plasma renin is usuallyPlasma renin is usually lowlow; ACE inhibition could be an; ACE inhibition could be an
effective short-term Rx for this low-renin HTNeffective short-term Rx for this low-renin HTN
⢠HTN-encephalopathy 5-10%.HTN-encephalopathy 5-10%. Improve without anyImprove without any
neurological sequelaeneurological sequelae
5050
51. Oliguria:Oliguria: 10-50%10-50%
⢠In 15%, UOP is <200mL. Oliguria is indicative of the severeIn 15%, UOP is <200mL. Oliguria is indicative of the severe
crescentic form of the dcrescentic form of the d
⢠Diuresis occurs within 1-2wDiuresis occurs within 1-2w
Left ventricular dysfunctionLeft ventricular dysfunction
⢠With/-out HTN or pericardial effusion may be presentWith/-out HTN or pericardial effusion may be present
during the acute congestive & convalescent phasesduring the acute congestive & convalescent phases
⢠Rarely, pulmonary hge occursRarely, pulmonary hge occurs
5151
53. Renal BiopsyRenal Biopsy
⢠Declining Renal FunctionDeclining Renal Function
⢠Atypical presentationAtypical presentation
⢠F/history of renal DF/history of renal D
⢠Persistent HTN or gross hematuriaPersistent HTN or gross hematuria
⢠HypocomplementemiaHypocomplementemia
Hallmark in PSGNHallmark in PSGN is subepithelial âhumpsâis subepithelial âhumpsâ
representing immune complex depositionrepresenting immune complex deposition
5353
54. DiagnosisDiagnosis
⢠CFCF
⢠Swab CS, positive ASO &/or anti-DNase BSwab CS, positive ASO &/or anti-DNase B
⢠C3 is typically low (normalizes 6-12w).C3 is typically low (normalizes 6-12w). But normalBut normal
C3 does not exclude itC3 does not exclude it
DDDD
⢠IgANIgAN
⢠HSPHSP
⢠SLESLE
⢠HUS, other inf.HUS, other inf. 5454
55. Rx Of APSGNRx Of APSGN
Mainly supportive.Mainly supportive. Bed restBed rest
⢠Fluid & salt restriction,Fluid & salt restriction, FEBFEB
⢠DiureticsDiuretics
⢠Rx of hyperkalemia.Rx of hyperkalemia. No fruits!No fruits!
⢠Penicillin x 10d: why?Penicillin x 10d: why?
⢠BP control. ACEI can cause hyperkalemiaBP control. ACEI can cause hyperkalemia
⢠Rx of complicationsRx of complications
⢠Admit if renal failureAdmit if renal failure
5555
56. APSGN: PrognosisAPSGN: Prognosis
⢠Excellent in childrenExcellent in children
⢠Most recover completelyMost recover completely
⢠Mortality <2%Mortality <2%
⢠CKD: 2% in children.CKD: 2% in children. 30% in adults30% in adults
⢠ESRD 1-2%ESRD 1-2%
⢠One attack confers lifelong immunity:One attack confers lifelong immunity: no recurrenceno recurrence
5656
58. SS of Glomerular DiseasesSS of Glomerular Diseases
May be silent for many yearsMay be silent for many years
⢠Hematuria, proteinuria, azotemiaHematuria, proteinuria, azotemia
⢠HTN, edema, hyperlipidemiaHTN, edema, hyperlipidemia
Some CRF can be slowed down, but scarredSome CRF can be slowed down, but scarred
glomeruli cannot be repairedglomeruli cannot be repaired
5858
59. GlomerularGlomerular vsvs Non-G Hematuria?Non-G Hematuria?
⢠Chemical trauma to RBCs occur while they pass throughChemical trauma to RBCs occur while they pass through
nephrons: peculiar changes: they lose biconcavity &nephrons: peculiar changes: they lose biconcavity &
have blebs:have blebs: âMickey Mouse CellsââMickey Mouse Cellsâ
⢠RBC casts & proteinuria supports a GDRBC casts & proteinuria supports a GD
5959
61. ProteinuriaProteinuria
Normal valuesNormal values
â Premature:Premature: â¤â¤ 140 mg/m140 mg/m22
/d/d
â Full TermFull Term â¤â¤ 70 mg/m70 mg/m22
/d/d
â Children <10yrChildren <10yr â¤â¤ 150 mg/d150 mg/d
â Children 10-18 yrChildren 10-18 yr â¤â¤ 300 mg/d300 mg/d
â AdultsAdults â¤â¤ 150 mg/d150 mg/d
6161
62. A 3y old child has heavy proteinuria with anasarca. NoA 3y old child has heavy proteinuria with anasarca. No
familial KD. No drugs. Wt 17 kg, BP 90/50; 4+ edemafamilial KD. No drugs. Wt 17 kg, BP 90/50; 4+ edema
Urine: 0-4 RBC/hpf. Numerous hyaline casts. Some lipidUrine: 0-4 RBC/hpf. Numerous hyaline casts. Some lipid
inclusions appearing Maltese cross under polarized lightinclusions appearing Maltese cross under polarized light
What is the Dx?What is the Dx?
6262
65. PeculiaritiesPeculiarities of Childhood NSof Childhood NS
⢠Most cases: no inflammation/RF (MCD)Most cases: no inflammation/RF (MCD)
⢠Most respond to steroidMost respond to steroid
⢠Well for 3y: no more relapseWell for 3y: no more relapse
⢠No relapse after 15yoaNo relapse after 15yoa
⢠Auto-remission 5%Auto-remission 5%
6565
66. ClassificationClassification
Acquired:Acquired:
Primary:Primary: MCNS/MCD (MCNS/MCD (85% of NS in children)85% of NS in children)
Secondary:Secondary:
Infection: APSGN, HBV, HCV, malariaInfection: APSGN, HBV, HCV, malaria
SLE, HSP, SCD, PAN, HTN, DMSLE, HSP, SCD, PAN, HTN, DM
amyloidosis, malignancyamyloidosis, malignancy
gold, penicillamine, Hg, Heavy metalgold, penicillamine, Hg, Heavy metal
membranoproliferativemembranoproliferative GN, mesangiocapillary GNGN, mesangiocapillary GN
diffuse proliferative GNdiffuse proliferative GN
CongenitaCongenitall
67. NS of childhoodNS of childhood
MCD: 85%
FSGS: 10%
Others: 5%
6767
FSGS: focal segmental glomerulosclerosis
68. EpidemiologyEpidemiology
⢠Incidence: 2-7/10,000/yIncidence: 2-7/10,000/y
⢠x15 common in childrenx15 common in children
⢠Non-immuneNon-immune factors in MCD & FSGSfactors in MCD & FSGS
⢠Immune factorsImmune factors in MPGN, APSGN & SLEin MPGN, APSGN & SLE
⢠Age of onset varies with type of diseaseAge of onset varies with type of disease
6868
69. Filtration membraneFiltration membrane
A. FenestratedA. Fenestrated endotheliumendothelium
B.B. GBM: 1. lamina interna 2. L. densa 3. L. externaGBM: 1. lamina interna 2. L. densa 3. L. externa
C.C. Podocytes: 1. enzymatic & structural protein 2. filtration slit 3. diaphragmPodocytes: 1. enzymatic & structural protein 2. filtration slit 3. diaphragm.
Disruption of slits or destruction of podocytes cause massive proteinuria
6969
70. Definitions:Definitions:
⢠Steroid sensitiveSteroid sensitive (90%)(90%)
⢠Steroid resistant:Steroid resistant: no response in 4w (10%)no response in 4w (10%)
⢠SteroidSteroid dependent:dependent: relapse on 2 consecutiverelapse on 2 consecutive
occasions as steroid is being tapered or within 2w ofoccasions as steroid is being tapered or within 2w of
being discontinuedbeing discontinued
⢠Remission:Remission: nil protein in morning urine x3dnil protein in morning urine x3d
⢠Relapse:Relapse: U. Protein: >40/m2/h or Albustix âĽ++ x 3d inU. Protein: >40/m2/h or Albustix âĽ++ x 3d in
morning urine sample, edemamorning urine sample, edema
Frequent R:Frequent R: âĽ2 in 6mo.âĽ2 in 6mo. oror âĽâĽ4/y4/y
7070
71. MCDMCD
⢠Commonest in children
⢠Biopsy:
â Light Microscopy: normal
â Electron microscopy: fusion of foot processes
⢠Immunofluorescent: no immune complex deposit
⢠Cause/mechanism unknown
⢠Drammatic response to steroid
⢠Excellent prognosis
7171
72. Focal Segmental GlomerulosclerosisFocal Segmental Glomerulosclerosis (FSGS) &(FSGS) &
Membranoproliferative GNMembranoproliferative GN (MPGN)(MPGN)
⢠In 15% of childhood NS. Biopsy shows scarring orIn 15% of childhood NS. Biopsy shows scarring or
deposits in glomerulideposits in glomeruli
⢠Steroid is less effective; need cytotoxicsSteroid is less effective; need cytotoxics
⢠ACEI can decrease HTN & proteinuriaACEI can decrease HTN & proteinuria
7272
73. C/FC/F
⢠M: F =2:1M: F =2:1
⢠Gross edema, scantyGross edema, scanty
urine, SoBurine, SoB
⢠There may be anThere may be an
antecedal URTI (specially in relapse)antecedal URTI (specially in relapse)
⢠Others:Others: depressiondepression, lethargy, anorexia, skin striae,, lethargy, anorexia, skin striae,
diarrhea, AP, orthostatic hypotensiondiarrhea, AP, orthostatic hypotension
Bedside urine: heavy proteinuriaBedside urine: heavy proteinuria
7373
76. InvestigationsInvestigations
⢠Urine RE, CS. Urinary total proteinUrine RE, CS. Urinary total protein
⢠Urinary albumin:creatinine (ACR) >200
Significant proteinuria: >4 mg/m2
/h
Heavy proteinuria: >40mg ,,
Remission: <4mg/ ,,
⢠CBC, electrolytes, BUN, S. Cr., S. albumin, AG ratio,CBC, electrolytes, BUN, S. Cr., S. albumin, AG ratio,
cholesterol (specifically LDL)cholesterol (specifically LDL)
⢠ANA; Anti-dsDNA, C3, HBsAg, HCVANA; Anti-dsDNA, C3, HBsAg, HCV
⢠Renal USGRenal USG
⢠CXR, MT, worms; before steroid Rx (eCXR, MT, worms; before steroid Rx (exclude TB, HBV, HCVxclude TB, HBV, HCV
or other inf)or other inf)
DD:DD: CHF, cirrhosis, protein losing statesCHF, cirrhosis, protein losing states 7676
77. Renal BiopsyRenal Biopsy
RarelyRarely done in Paediatric cases.done in Paediatric cases. Consider in:Consider in:
⢠Cong. NSCong. NS
⢠>8y at onset>8y at onset
⢠Steroid resistanceSteroid resistance
⢠Frequent relapsesFrequent relapses
⢠Significant nephritic featuresSignificant nephritic features
7777
78. ComplicationsComplications
⢠Infection:Infection: loss of Ig, complement: UTI, SBP (commonest)loss of Ig, complement: UTI, SBP (commonest)
& pneumonia& pneumonia (pneumococcus)(pneumococcus)
⢠Thrombosis:Thrombosis: loss of antithrombin iii, antiplasmin &loss of antithrombin iii, antiplasmin &
proteins S & C in urine, more coagulants by liver,proteins S & C in urine, more coagulants by liver,
raised hct., relative immobility, steroidraised hct., relative immobility, steroid
⢠Hypovolemia:Hypovolemia: postural hypotensionpostural hypotension
⢠From Drug toxicity:From Drug toxicity: steroid, nephrotoxcity fromsteroid, nephrotoxcity from
cyclosporin A or tacrolimuscyclosporin A or tacrolimus
7878
79. Management: GeneralManagement: General
⢠CheckCheck BP, wt, abdo. girth, I.O. chart, proteinuriaBP, wt, abdo. girth, I.O. chart, proteinuria
⢠Bed rest in gross edemaBed rest in gross edema
⢠Diet: lean proteinDiet: lean protein (no role of excess protein),(no role of excess protein), low fatlow fat
⢠Salt & fluid restrictionSalt & fluid restriction
⢠UsuallyUsually no diureticno diuretic
⢠Hypovolemia & hypoalbuminemia: FFP 20ml/kg or saltHypovolemia & hypoalbuminemia: FFP 20ml/kg or salt
poor albumin 20%poor albumin 20%
⢠Anticoagulants can help decrease clottingAnticoagulants can help decrease clotting
⢠Statins can help lower cholesterolStatins can help lower cholesterol
7979
80. RxRx
â˘Corticosteroids is the first step in Rx of MCD & biopsy is notCorticosteroids is the first step in Rx of MCD & biopsy is not
indicated.indicated. For steroid meet all these criteria:For steroid meet all these criteria:
â˘Age 1-8y. Normal kidney functionAge 1-8y. Normal kidney function
â˘No macroscopic hematuriaNo macroscopic hematuria
â˘No systemic features: F, rash, joint pain, wt lossNo systemic features: F, rash, joint pain, wt loss
â˘Normal complement levels. Negative ANANormal complement levels. Negative ANA
â˘Negative HIV, hepatitis B&CNegative HIV, hepatitis B&C
â˘No FH of kidney dNo FH of kidney d
8080
81. Kidney biopsyKidney biopsy is done if 1 or more of the following:is done if 1 or more of the following:
â˘Age <1y or >8yAge <1y or >8y
â˘Recurrent gross hematuriaRecurrent gross hematuria
â˘Relevant FH of kidney d., symptoms of systemic dRelevant FH of kidney d., symptoms of systemic d
â˘Positive viral screensPositive viral screens
â˘Additional criteria are lab. findings possibly indicative ofAdditional criteria are lab. findings possibly indicative of
2y NS or Idiopathic NS other than MCD:2y NS or Idiopathic NS other than MCD:
â Sustained raised creatinineSustained raised creatinine
â Low C3/C4 levels. Positive ANA. Positive antiâds-DNA antibodyLow C3/C4 levels. Positive ANA. Positive antiâds-DNA antibody
â˘Here, histology guides Rx, & steroids may/may not beHere, histology guides Rx, & steroids may/may not be
indicated depending on the underlying causeindicated depending on the underlying cause
8181
82. ⢠In selected preadolescent >8y (â¤12 y), empirical steroidIn selected preadolescent >8y (â¤12 y), empirical steroid
Rx can be considered prior to kidney biopsy only under aRx can be considered prior to kidney biopsy only under a
pediatric nephrologist. Children >12y requirepediatric nephrologist. Children >12y require
biopsy due to the rising incidencebiopsy due to the rising incidence
of FSGS & other c/of nephrosisof FSGS & other c/of nephrosis
⢠Initial Rx:Initial Rx: Oral prednisone, 60mg/mOral prednisone, 60mg/m22
/d or 2mg/kg/d (max.,/d or 2mg/kg/d (max.,
60mg/d) 4â6w. Then, 40mg/m60mg/d) 4â6w. Then, 40mg/m22
or 1.5mg/kg (max.,or 1.5mg/kg (max., 40mg)40mg)
EAD 2â5mo with tapering, with a min. 12wEAD 2â5mo with tapering, with a min. 12w
8282
83. ⢠Infrequent relapseInfrequent relapse (1 in 6mo or 1-3 in 12mo): dose(1 in 6mo or 1-3 in 12mo): dose (60(60
mg/mmg/m22
/d or 2mg/kg/d) until urinary protein is nil/d or 2mg/kg/d) until urinary protein is nil
x3d; then, 40mg/mx3d; then, 40mg/m22
or 1.5 mg/kg (max., 40mg)or 1.5 mg/kg (max., 40mg)
EAD for 4w,EAD for 4w, then stop or taperthen stop or taper
⢠Rx of frequent relapseRx of frequent relapse: continue infrequent relapse Rx: continue infrequent relapse Rx
for 3mo at lowest dose to maintain remission or usefor 3mo at lowest dose to maintain remission or use
steroid-sparing agents, alkylating agents,steroid-sparing agents, alkylating agents,
levamisole, calcineurin inhibitors,levamisole, calcineurin inhibitors,
mycophenolate mofetilmycophenolate mofetil
8383
84. Steroid Resistant NSSteroid Resistant NS
⢠Refer to specialized unitRefer to specialized unit
⢠Full remission not achievedFull remission not achieved
⢠Aim: lower proteinuria to non-nephrotic rangeAim: lower proteinuria to non-nephrotic range
⢠Risk of HTN & renal failureRisk of HTN & renal failure
⢠In FSGS: 20-40% risk of post transplant relapseIn FSGS: 20-40% risk of post transplant relapse
8484
85. SSNSSSNS
⢠Toddler, pre-school
⢠No HTN
⢠Hematuria: Mild,
intermittent
⢠Normal renal function
⢠Excellent prognosis,
even if frequently
relapsing
⢠No biopsy
SRNSSRNS
⢠<1 year, > 8y
⢠HTN common
⢠Persistent
⢠Often abnormal RF
⢠Long term HTN & RF
⢠Biopsy needed: usual
histology FSGS
8585
86. Congenital NSCongenital NS
⢠First 3 mo of life. Large placenta: ~ 40% of BWFirst 3 mo of life. Large placenta: ~ 40% of BW
⢠Drug resistant. High morbidity: PEM & sepsisDrug resistant. High morbidity: PEM & sepsis
⢠Types:Types: Finnish type:Finnish type: most severe, AR.most severe, AR. Diffuse mesangialDiffuse mesangial
sclerosis:sclerosis: less severe, AR.less severe, AR. Denys-Drash syn.:Denys-Drash syn.:
pseudohermaphroditism & Wilms T.pseudohermaphroditism & Wilms T. FSGS.FSGS. Secondary CNS:Secondary CNS:
cong. syphiliscong. syphilis
⢠Rx.:Rx.: Intensive care: 20% albumin, nutrition, earlyIntensive care: 20% albumin, nutrition, early
unilateral nephrectomy, RRTunilateral nephrectomy, RRT
8686
87. RxRx of Hypertension in NSof Hypertension in NS
⢠ACEI reduce BP & proteinuriaACEI reduce BP & proteinuria
⢠NifedipineNifedipine 0.25mg/kg/dose s.l.; max 8 doses/d (not0.25mg/kg/dose s.l.; max 8 doses/d (not
>2mg/kg/d or>2mg/kg/d or
⢠HydralazineHydralazine 0.5-2mg/kg/d)0.5-2mg/kg/d)
⢠Others:Others: Atenolol, MethyldopaAtenolol, Methyldopa
⢠DiureticDiuretic isis ccontroversial. Use with caution. May beontroversial. Use with caution. May be
dangerous indangerous in hypovolemiahypovolemia
S.l.: sub lingualS.l.: sub lingual
8787
88. Immunization in NSImmunization in NS
Immunocompromized:Immunocompromized: steroid 2mg/kg/d orsteroid 2mg/kg/d or 20mg/d x20mg/d x 14d14d
⢠No live vax.No live vax.
⢠Killed vax./toxoids are safeKilled vax./toxoids are safe
⢠Live vax. after 4w of stopping steroidLive vax. after 4w of stopping steroid
⢠VZIG in case of exposureVZIG in case of exposure
⢠Ig in case of measles expo. or cl. measlesIg in case of measles expo. or cl. measles
8888
91. MCQMCQ
⢠In APSGN ABT is essentialIn APSGN ABT is essential for the pt.for the pt.
⢠APSGN is an autoimmune DAPSGN is an autoimmune D
⢠Strep. skin infx. can cause Rh. FStrep. skin infx. can cause Rh. F
⢠Fruits are beneficial in APSGNFruits are beneficial in APSGN
⢠In APSGN LVF can occur from myocarditisIn APSGN LVF can occur from myocarditis
⢠Hyperkalemia is a recognized complication ofHyperkalemia is a recognized complication of
APSGNAPSGN
9191
92. MCQMCQ
⢠MCD is common after 8yoaMCD is common after 8yoa
⢠NS Dx always needs renal biopsyNS Dx always needs renal biopsy
⢠Hematuria is common in childhood NSHematuria is common in childhood NS
⢠Levamisole is effective in relapse NSLevamisole is effective in relapse NS
⢠Usually there is renal failure in NSUsually there is renal failure in NS
⢠MCD is an AIDMCD is an AID
9292
Papilloma is a benign epithelial T growing outward in nipple-like & often finger-like fronds. It refers to the projection created by the T, not a tumor of a papilla (nipple)
Renal cell Ca (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. RCC occurs when Ca cells start growing uncontrollably in the lining of tubules. RCC is a fast-growing cancer & often spreads to the lungs & surrounding organs
HSP: a immune-related, small-BV vasculitis. IgA-C3 immune complex deposits in BV & elsewhere. Cause is unknown. Commonest in 3-8y (commonest vasculitis of childhood)
Incidence: 1/5000 children/y; occurs in adults too. Many have strong atopy, & usually follow URTI. It may be that deposition of IgA & C3 is related to an overzealous immune response to a preceding inf. IF: prominent deposition of IgA (sometimes IgG & C3) in the mesangial region; pattern looks so much like IgAN (best to think of HSP & IgAN as faces of the same d)
Rx is usually supportive. Steroids may reduce the chance of severe renal d. In some cases, it recurs, usually manifesting with bouts of hematuria
Proliferative extracapillary GN or crescentic GN is not a specific d, but a feature of severe glomerular damage. Extracapillary proliferation designates the cellular and/or fibrous proliferation that occupies the Bowmanâs space. There is no universal agreement on the percentage of involved glomeruli to diagnose crescentic GN: usually &gt; or = 50%. Definition of crescent is the presence of at least 2 layers of cells that are filling totally or partially Bowmanâs space
WAGR syn (aka WAGR complex: Wilms T-aniridia syn, aniridia-Wilms T syn) is a rare genetic syn in which affected children are predisposed to develop WT, Aniridia, GU anomalies, & mental Retardation. The G is sometimes instead given as &quot;gonadoblastoma,&quot; since the GU anomalies can include T of the gonads (testes or ovaries).[A subset of WAGR shows severe childhood obesity; the acronym WAGROhas been used to describe this category.
The condition, first described by Miller et al. in 1964 in its association with other congenital malformations,[4] results from a deletion on chromosome 11 resulting in the loss of several genes. As such, it is one of the best studied examples of a condition caused by loss of neighbouring (contiguous) genes.[3]
It is possible for those with WAGR to develop WT, a rare form of kidney cancer
Mechanical hemolytic a. is due to mechanically induced damage to rbc. RBCs, while flexible, may in some circumstances succumb to physical shear & compression. This may result in hemoglobinuria. The damage is c/by repetitive mechanical motions like prolonged marching (march hb.uria), marathon running, &  bongo drumming. Mechanical damage can also be due to chr. condition: microangiopathic hemolytic a or due to prosthetic heart valves.[1]
Glomerular mesangium is a/with the capillaries. It is continuous with the smooth m of the arterioles; outside the lumen, but surrounded by capillaries. It is in the middle (meso) between the capillaries (angis). Both are contained by same BM. This term is often used interchangeably with mesangial cell, but in this context refers specifically to the intraglomerular mesangial cells. These cells are phagocytic & secrete BM (mesangial matrix). They are typically separated from the lumen of the capillaries by endothelial cells
ATN is death of tubular epithelial cells. Common c/of: low BP & nephrotoxics. ATN is the most common c/of AKI in the renal category. ATN follows a well-defined three-part sequence of initiation, maintenance, & recovery.
The initiation phase is an acute decrease in GFR to very low levels, with a sudden increase in serum creatinine & BUN.
The maintenance phase is a sustained severe reduction in GFR that persists for a variable length of time, most commonly 1-2 w., the creatinine & BUN levels continue to rise.
The recovery phase, in which tubular function is restored, is characterized by an increase in urine volume (if oliguria was present during the maintenance phase) & by a gradual decrease in BUN & creatinine to their preinjury levels.
The tubule cell damage & cell death that characterize ATN usually result from an acute ischemic or toxic event. Nephrotoxic mechanisms of ATN include direct drug toxicity, intrarenal vasoconstriction, & intratubular obstruction. Most of the pathophysiologic features of ischemic ATN are shared by the nephrotoxic forms.
The history, PE,& lab, especially the renal USG & urinalysis, are particularly helpful in identifying the c/of ATN.
Therapeutic mainstays are prevention, avoidance of further kidney damage, Rx of underlying conditions, & aggressive Rx of complications.
Pathophysiology
Acute tubular necrosis (ATN) follows a well-defined three-part sequence of initiation, maintenance,&recovery (see below). The tubule cell damage&cell death that characterize ATN usually result from an acute ischemic or toxic event. Most of the pathophysiologic features of ischemic ATN, as described below, are shared by the nephrotoxic forms.
Initiation phase
Ischemic ATN is often described as a continuum of prerenal azotemia. Indeed, the causes of the two conditions are the same. Ischemic ATN results when hypoperfusion overwhelms the kidneyâs autoregulatory defenses. Under these conditions, hypoperfusion initiates cell injury that often, but not always, leads to cell death.
Injury of tubular cells is most prominent in the straight portion of the proximal tubules&in the thick ascending limb of the loop of Henle, especially as it dips into the relatively hypoxic medulla. The reduction in the glomerular filtration rate (GFR) that occurs from ischemic injury is a result not only of reduced filtration due to hypoperfusion but also of casts&debris obstructing the tubule lumen, causing back-leak of filtrate through the damaged epithelium (ie, ineffective filtration).
The earliest changes in the proximal tubular cells are apical blebs&loss of the brush border membrane followed by a loss of polarity&integrity of the tight junctions. This loss of epithelial cell barrier can result in the above-mentioned back-leak of filtrate.
Another change is relocation of Na+/K+-ATPase pumps&integrins to the apical membrane. Cell death occurs by both necrosis&apoptosis. Sloughing of live&dead cells occurs, leading to cast formation&obstruction of the tubular lumen (see the image below).
In addition, ischemia leads to decreased production of vasodilators (ie, nitric oxide, prostacyclin [prostaglandin I2, or PGI2]) by the tubular epithelial cells, leading to further vasoconstriction&hypoperfusion.
On a cellular level, ischemia causes depletion of adenosine triphosphate (ATP), an increase in cytosolic calcium, free radical formation, metabolism of membrane phospholipids,&abnormalities in cell volume regulation. The decrease or depletion of ATP leads to many problems with cellular function, not the least of which is active membrane transport.
With ineffective membrane transport, cell volume&electrolyte regulation are disrupted, leading to cell swelling&intracellular accumulation of sodium&calcium. Typically, phospholipid metabolism is altered,&membrane lipids undergo peroxidation. In addition, free radical formation is increased, producing toxic effects. Damage inflicted by free radicals apparently is most severe during reperfusion.
Maintenance phase
The maintenance phase of ATN is characterized by a stabilization of GFR at a very low level,&it typically lasts 1-2 weeks. Complications (eg, uremic&others; see Complications) typically develop during this phase.
The mechanisms of injury described above may contribute to continued nephron dysfunction, but tubuloglomerular feedback also plays a role. Tubuloglomerular feedback in this setting leads to constriction of afferent arterioles by the macula densa cells, which detect an increased salt load in the distal tubules.
Recovery phase
The recovery phase of ATN is characterized by regeneration of tubular epithelial cells. [2] During recovery, an abnormal diuresis sometimes occurs, causing salt&water loss&volume depletion. The mechanism of the diuresis is not completely understood, but it may in part be due to the delayed recovery of tubular cell function in the setting of increased glomerular filtration. In addition, continued use of diuretics (often administered during initiation&maintenance phases) may also add to the problem.
Normotensive Ischemic Acute Tubular Necrosis
This is a condition that develops in patients without an overt severe hypotensive episode. These patients have low-normal blood pressure but still have severe ATN. The most common reason for this condition is renal susceptibility to the lower blood pressure because of impairment of autoregulatory function of the kidney. Normally, the afferent arteriole dilates (via prostaglandins)&efferent arteriole constricts (via angiotensin-II) to maintain the glomerular capillary pressure. Factors that impair this autoregulatory mechanisms include the following [3] :
Advanced age
Atherosclerosis, hypertension,&chronic kidney disease
Malignant hypertension
Medications impairing the autoregulatory mechanism (eg, nonsteroidal anti-inflammatory drugs [NSAIDs])
Afferent glomerular vasoconstriction (eg, from sepsis, hypercalcemia, hepatorenal syndrome, cyclosporine/tacrolimus)
Drugs blocking efferent arteriolar vasoconstriction - Angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs)
Endotoxemia (sepsis)-related ATN
Sepsis is a recognized cause of ATN. However, the hypothesis that ATN develops in these cases when sepsis-related hypotension leads to a reduction in renal blood flow has been challenged by several animal&human studies. Those studies have indicated that in fact, renal blood flow may increase in that setting, due to a mechanism leading to efferent arteriolar vasodilatation. [4]
Other suspected contributors to ATN in sepsis include the following:
Intra-renal vasoconstriction&redistribution of renal blood flow to the cortex
Activation of vasoactive intrarenal hormones (endothelin, renin-angiotensin- aldosterone)
Nitric oxide synthase induction&release of several cytokines
Â
Etiology
ATN is generally caused by an acute event, either ischemic or toxic.
Causes of ischemic acute tubular necrosis
Ischemic ATN may be considered part of the spectrum of prerenal azotemia,&indeed, ischemic ATN&prerenal azotemia have the same causes&risk factors. Specifically, these include the following:
Hypovolemic states: Hemorrhage, volume depletion from gastrointestinal (GI) or renal losses, burns, fluid sequestration
Low cardiac output states: Heart failure&other diseases of myocardium, valvulopathy, arrhythmia, pericardial diseases, tamponade
Systemic vasodilation: Sepsis, anaphylaxis
Disseminated intravascular coagulation
Causes of nephrotoxic acute tubular necrosis
The kidney is a particularly vulnerable target for toxins, both exogenous&endogenous. Not only does it have a rich blood supply, receiving 25% of cardiac output, but it also helps in the excretion of these toxins by glomerular filtration&tubular secretion.
Exogenous nephrotoxins that cause ATN
Aminoglycoside-related toxicity occurs in 10-30% of patients receiving aminoglycosides, even when blood levels are in apparently therapeutic ranges. Risk factors for ATN in these patients include the following:
Preexisting liver or renal disease
Concomitant use of other nephrotoxins (eg, amphotericin B, radiocontrast media, cisplatin)
Shock
Advanced age
Female sex
Higher aminoglycoside level 1 hour after dose (a high trough level has not been shown to be an independent risk factor)
Amphotericin B nephrotoxicity risk factors include the following:
Male sex
High maximum daily dose (nephrotoxicity is more likely to occur if &gt;3 g is administered)
Longer duration of therapy
Hospitalization in the critical care unit at the initiation of therapy
Concomitant use of cyclosporine
Radiographic contrast media can cause contrast-induced nephropathy (CIN) or radiocontrast nephropathy (RCN); this commonly occurs in patients with several risk factors, such as elevated baseline serum creatinine, preexisting renal insufficiency, underlying diabetic nephropathy, chronic heart failure [CHF], or high or repetitive doses of contrast media, as well as volume depletion&concomitant use of diuretics, ACE inhibitors, or ARBs. The 2011 UKRA guidelines recommend that patients at risk of CIN should have a careful evaluation of volume status&receive volume expansion with 0.9% sodium chloride or isotonic sodium bicarbonate before the procedure. [5]
Other exogenous nephrotoxins that can cause ATN include the following:
Cyclosporine&tacrolimus (calcineurin inhibitors)
Cisplatin
Ifosfamide
Foscarnet
Pentamidine, which is used to treat Pneumocystis jiroveci infection in immunocompromised individuals (risk factors for nephrotoxicity include volume depletion&concomitant use of other nephrotoxic antibiotic agents, such as aminoglycosides, which is common practice in the immunosuppressed)
Sulfa drugs
Acyclovir&indinavir
Mammalian target of rapamycin (mTOR) inhibitors (eg, everolimus, temsirolimus)Â [6]
Endogenous nephrotoxins that cause ATN
In myoglobinuria, rhabdomyolysis is the most common cause of heme pigmentâassociated acute kidney injury (AKI)&can result from traumatic or nontraumatic injuries. Most cases of rhabdomyolysis are nontraumatic, such as those related to alcohol abuse or drug-induced muscle toxicity (eg, statins alone or in combination with fibrates).
In hemoglobinuria, AKI is a rare complication of hemolysis&hemoglobinuria,&most often is associated with transfusion reactions (in contrast to myoglobin, hemoglobin has no apparent direct tubular toxicity,&AKI in this setting is probably related to hypotension&decreased renal perfusion). [6]
Acute crystal-induced nephropathy occurs when crystals are generated endogenously due to high cellular turnover (ie, uric acid, calcium phosphate), as observed in certain malignancies or the treatment of malignancies. However, this condition is also associated with ingestion of certain toxic substances (eg, ethylene glycol) or nontoxic substances (eg, vitamin C). Choudhry et al reported a case of AKI caused by ingestion of excessive quantities of calcium-containing antacids. [7]
In multiple myeloma, renal impairment results from the accumulation&precipitation of light chains, which form casts in the distal tubules that cause renal obstruction. In addition, myeloma light chains have a direct toxic effect on proximal renal tubules. [8]
Prognosis
For patients with ATN, the in-hospital survival rate is approximately 50%, with about 30% of patients surviving for 1 year. Factors associated with an increased mortality rate include the following:
Poor nutritional status
Male sex
Oliguria
Need for mechanical ventilation
Acute myocardial infarction
Stroke
Seizures
The mortality rate in patients with ATN is probably related more to the severity of the underlying disease than to ATN itself. For example, the mortality rate in patients with ATN after sepsis or severe trauma is much higher (about 60%) than the mortality rate in patients with ATN that is nephrotoxin related (about 30%). The mortality rate is as high as 60-70% with patients in a surgical setting. If multiorgan failure is present, especially severe hypotension or acute respiratory distress syndrome, the mortality rate ranges from 50 to 80%.
Patients with oliguric ATN have a worse prognosis than patients with nonoliguric ATN. This probably is related to more severe necrosis&more significant disturbances in electrolyte balance. In addition, a rapid increase in serum creatinine (ie, &gt;3 mg/dL) probably also indicates a poorer prognosis. Again, this probably reflects a more serious underlying disease.
Of the survivors of ATN, approximately 50% have some impairment of renal function. Some (about 5%) continue to undergo a decline in renal function. About 5% never recover kidney function&require dialysis.
A review of United States Renal Data System data (n = 1,070,490) for 2001 through 2010 found that  although the incidence of end-stage renal disease (ESRD) attributed to ATN increased during that period, the prospects for renal recovery&survival also increased. Recovery of renal function was more likely in patients with ATN than in matched controls (cumulative incidence 23% vs. 2% at 12 weeks, 34% vs. 4% at 1 year), as was death (cumulative incidence 38% vs. 27% at 1 year). Hazards ratios for death declined in stepwise fashion to 0.83 in 2009-2010. [9]
For post AKI hospitalization outcomes&monitoring see Treatment/Long-Term Monitoring
Â
Â
Epidemiology
The landmark PICARD (Program to Improve Care in Acute Renal Disease) study was an observational study of a cohort of 618 patients with acute kidney injury in the intensive care units of 5 academic centers in the United States. Ischemic ATN was the presumed etiology for 50% of all patients with renal failure, an additional ~12% due to unresolved pre-renal factors,&~25% from nephrotoxic ATN. [10]  These data were similar to those from the Madrid Acute Renal Failure Study Group
Alport Syn? hematuria as the commonest & males affected more severely; can also affect cochlea & eye. Prevalence: 1/5,000. C/by mutations affecting type IV collagen, a major part of basement m. 80% X-linked. 20% is AR/AD
Kidneys: always affected. Hematuria is usually microscopic; sometimes for several days, associated with a cold or flu. This gross hematuria eventually stops when the child recovers & can be very frightening but is not harmful. As boys get older, they begin to show additional signs: proteinuria & HTN. These usually occur by the time the boys are teenagers. AS causes damage to the kidneys by formation of scar (glomeruli & tubules). Proteinuria damages the filtering system or glomeruli because of the abnormal collagen makeup (fibrosis: CKD). X-linked Alport develops CRF by the teenage years or early adulthood, but the onset of kidney failure can be delayed 40-50y of age. Carriers have no kidney failure. However, as women age, the risk of kidney failure increases. AD is usually well into middle age before CRF
Inner Ear: Hearing loss is never present at birth but becomes apparent by late childhood or early adolescence, generally before CRF. Some families have no deafness. Hearing aids are usually v effective. 80% of boys with X-linked AS develop hearing loss at some point in their lives, often by the time they are teenagers. In girls with X-linked AS hearing loss is less frequent & occurs later in life. AR typically have childhood hearing loss. Patients with AD develop hearing loss at a later age
Eyes: Anterior lenticonus is an abnormality in the shape of the lens of the eye (15-20% of X-linked & AR). People with anterior lenticonus may have a slow progressive deterioration of vision requiring patients to change the prescription of their glasses frequently. This condition may also lead to cataract formation. Some people have abnormal pigment of the retina called dot-and-fleck retinopathy, but this does not result in any abnormalities of vision. Recurrent corneal erosion can occur; & may need to take measures to protect their corneas from minor trauma such as wearing goggles when riding a bicycle
BUN measures amount of N in blood urea from protein metabolism. BUN test is done to see how  kidneys work. HF, dehydration, or a diet high in protein can also make it higher. Liver d/damage can lower it. A low BUN level can occur normally in 2TM/3tm of preg
Goodpasture syn: a rare d that can quickly worsen. RF & lung d. Some forms involve just the lung or the kidney, but not both.
Causes: AID; mistakenly attacks & destroys collagen in alveoli & GBM. Sometimes is triggered by a viral resp inf or by breathing in hydrocarbon solvents. In such cases, the immune system may attack organs or tissues because it mistakes them for these viruses or foreign chemicals. The immune system&apos;s faulty response causes bleeding in the air sacs of the lungs & inflam in the kidney. Men are x8 likely. It commonly occurs in early adulthood.
Symptoms: may occur very slowly over months or even years, but they often develop v quickly over days to weeks. Anorexia, fatigue, & weakness are common. Lungs: Coughing up blood, Dry cough, SoB.
Kidney & other symptoms: Bloody urine, dysuria, NV, Pallor, edema
Exams & Tests
PE: HTN, & fluid overload. abnormal heart & lung sounds.
Urinalysis usually abnormal: blood & protein in urine. Abnormal rbc may be seen.
Tests: Anti-GBM, ABG, BUN, CXR, Creatinine, Lung biopsy, Kidney biopsy
Rx.: goal is to remove harmful Ab. Plasmapheresis removes whole blood from the body & replaces the plasma with fluid, protein, or donated plasma. Removing harmful Ab may reduce inflam in the kidneys & lungs.
Prednisone & other drugs suppress or quiet the immune system.
Controlling BP is the most important way to delay kidney damage. ACEI inhibitors & ARBs. Salt & fluids limit. A low to moderate protein may be recommended.
Closely watch kidney failure. Dialysis. Kidney transplant. A transplant is not done until the level of harmful antibodies drops.
Outlook: An early Dx is v imp. Much worse if the kidneys are severely damaged. Lung damage can range from mild to severe. Many need dialysis or transplant.
Complications: CKD, ESRD, Lung failure, Rapidly progressive GN, Severe lung bleeding
Prevention
Never sniff glue or siphon gasoline with your mouth, which expose the lungs to hydrocarbon & can cause the disease.
Alternative Names
Anti-glomerular basement membrane antibody disease; Rapidly progressive glomerulonephritis with pulmonary hemorrhage; Pulmonary renal syndrome; Glomerulonephritis - pulmonary hemorrhageAnti-glomerular basement membrane antibody disease; Rapidly progressive glomerulonephritis with pulmonary hemorrhage; Pulmonary renal syndrome; Glomerulonephritis - pulmonary hemorrhage
PNH (Marchiafava-Micheli syn.) Hb.uria & thrombosis. PNH is the only hemolytic a. which is mostly c/by an acquired intrinsic defect in CW (deficiency of glycophosphatidylinositol). It may be primary or in aplastic a. 26% have the telltale red urine in the morning. Allogeneic BMT is the only cure, but has significant MM. Eculizumab is effective, improving QoL, & reducing the risk of thrombosis
Myelodysplastic Syndromes (MDS) are a group of diverse BM d in which BM does not produce enough healthy cells. It is often referred to as a âBM failure dâ. MDS is primarily a d of the elderly (most &gt;65), but can affect younger pts. as well. Stem cells, progenitor cells, or blasts â that normally mature; in MDS, they may not mature & may accumulate or may have a shortened life span, resulting in fewer than normal mature cells in blood. Low blood cell counts or cytopenias, are a hallmark of MDS: inf, anemia, bleeding. In addition to reduced numbers of cells, the mature blood cells circulating may not function properly because of dysplasia. The formal definition of dysplasia is the abnormal shape&appearance, or morphology, of a cell. Myelodysplasia refers to the abnormal shape&appearance of the mature blood cells. Failure of BM to produce mature healthy cells is a gradual process,&therefore MDS is not necessarily a terminal d. Some patients do succumb to the direct effects of the d. In addition, for roughly 30% of pts. Dx with MDS, this type of BM failure syndrome will progress to AML
Gene is called PIG-A.Â
BMT: BM transplantation
IF: Immunofluorescence
Anti-DNase BÂ is test for Ab to a protein made by GAS. When used together with ASO, &gt;90% of past GAS inf can be Dx. If SS of Rh F or AGN are present, a raised anti-DNase BÂ &/or ASOÂ may be used to confirm Dx.
The complements are 60 proteins, 30 circulating blood that work together to promote immune & inflam responses. Complement tests measure the amount or activity of them. Most commonly C3 & C4, are used to determine if abnormalities in complements are causing, or contributing to, a d. Complement testing may be used to:
1. Help Dx the c/of recurrent microbial inf (S pn., N meningitides, N gonorrhea), angioedema, or inflam
2. Help Dx & monitor activity & Rx of ac./chr. AID (SLE & RhA)
3. Monitor immune complex-related d & conditions (GN, serum sickness, & vasculitis)
FEB: fluid & electrolyte balance
Podocytes in Bowman capsule that wrap capillaries with long foot processes. They have slit diaphragm or filtration slit. Podocytes can regulate GFR by contraction/closure of filtration slits